ANDA 78517, held by PLIVA Hrvatska. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 78517 (Venlafaxine Hydrochloride), held by PLIVA Hrvatska, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Tentative approval | None posted |
| Venlafaxine HydrochlorideEQ 25MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 37.5MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 50MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 75MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 100MG BASE ยท tablet;oral | Venlafaxine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters